HomeStock ScreenerVenus RemediesIntrinsic Value

Venus Remedies Intrinsic Value

Venus Remedies (VENUSREM) median intrinsic value is ₹863.08 from 9 valuation models (range ₹386–₹1325), vs current price ₹1030.55 — -16.3% downside (Trading Above Median Value), margin of safety -19.4%. Also explore VENUSREM share price data to track price trends across different timeframes.

Current Stock Price
₹1030.55
Primary Intrinsic Value
₹1325.28
Market Cap
₹1340 Cr
-16.3% Downside
Median Value
₹863.08
Value Range
₹386 - ₹1325
Assessment
Trading Above Median Value
Safety Margin
-19.4%

VENUSREM Valuation Methods Summary — DCF, Graham Number & P/E

Venus Remedies intrinsic value across 9 models vs current price ₹1030.55 — upside/downside and value range per method. For current market price and key ratios, visit Venus Remedies share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1325.28 ₹1060.22 - ₹1590.34 +28.6% EPS: ₹60.24, Sector P/E: 22x
Book Value Method asset ₹863.08 ₹776.77 - ₹949.39 -16.3% Book Value/Share: ₹431.54, P/B: 2.0x
Revenue Multiple Method revenue ₹1200.00 ₹1080.00 - ₹1320.00 +16.4% Revenue/Share: ₹600.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹1015.38 ₹913.84 - ₹1116.92 -1.5% EBITDA: ₹132.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹614.16 ₹491.33 - ₹736.99 -40.4% CF Growth: 5.0%, Discount: 15%
PEG Ratio Method growth ₹385.54 ₹346.99 - ₹424.09 -62.6% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹930.71 ₹837.64 - ₹1023.78 -9.7% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹738.46 ₹664.61 - ₹812.31 -28.3% ROE: 14.3%, P/E Multiple: 12x
Graham Defensive Method conservative ₹764.79 ₹688.31 - ₹841.27 -25.8% EPS: ₹60.24, BVPS: ₹431.54
Method Types: Earnings Asset DCF Growth Dividend Conservative

VENUSREM Intrinsic Value vs Market Price — All Valuation Models

Venus Remedies fair value range ₹386–₹1325 vs current market price ₹1030.55 across 9 valuation models. Browse VENUSREM complete financial statements for revenue, profit, balance sheet and cash flow data.

VENUSREM Intrinsic Value Analysis — Undervalued or Overvalued?

Venus Remedies median intrinsic value ₹863.08, current price ₹1030.55 — Trading Above Median Value by 16.3%, margin of safety -19.4%.

What is the intrinsic value of VENUSREM?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Venus Remedies (VENUSREM) is ₹863.08 (median value). With the current market price of ₹1030.55, this represents a -16.3% variance from our estimated fair value.

The valuation range spans from ₹385.54 to ₹1325.28, indicating ₹385.54 - ₹1325.28.

Is VENUSREM undervalued or overvalued?

Based on our multi-method analysis, Venus Remedies (VENUSREM) appears to be trading above median value by approximately 16.3%.

VENUSREM Financial Health — Key Ratios vs Industry Benchmarks

Venus Remedies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 23.79 Industry Standard: 2.0+ Above 2.0 Measures short-term liquidity capacity
Return on Equity 14.3% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 16.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 1.09x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

VENUSREM Cash Flow Quality — Operating & Free Cash Flow

Venus Remedies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹86 Cr ₹48 Cr Positive Free Cash Flow 8/10
March 2024 ₹37 Cr ₹33 Cr Positive Free Cash Flow 8/10
March 2023 ₹37 Cr ₹8 Cr Positive Free Cash Flow 7/10
March 2022 ₹41 Cr ₹33 Cr Positive Free Cash Flow 8/10
March 2021 ₹132 Cr ₹132 Cr Positive Free Cash Flow 8/10